- Home
- MSD vs PLX Comparison
MSD vs PLX Comparison
Compare MSD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSD | PLX |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 159.5M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | MSD | PLX |
|---|---|---|
| Price | $7.35 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 82.7K | ★ 890.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.59 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.91 | $1.34 |
| 52 Week High | $7.94 | $3.19 |
Technical Indicators
Market Signals| Indicator | MSD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 52.89 |
| Support Level | $7.25 | $2.06 |
| Resistance Level | $7.49 | $2.16 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 49.18 | 77.05 |
Price Performance
Historical ComparisonAbout MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.